

OFFICIAL

FAX RECEIVED

NOV 30 1998

GROUP 1600

Serial No.: 08/955,373

Atty. Docket No.: 162/P58774US3

Sub
E2
effective amount of an immunogenic composition [according to claim
16] ~~comprising at least one modified self-protein and at least one
immunologically acceptable adjuvant.~~

Please add the following new claims 28-44.

--28. The method of claim 25, wherein the adjuvant is selected from the group consisting of calcium, phosphate, saponin, quil A and biodegradable polymers.

E2
29. The method of claim 26, wherein the modified self-protein is fused to at least one suitable, immunologically active cytokine.

30. The method of claim 29, wherein the immunologically active cytokine is selected from the group consisting of GM-CSF and interleukin 2.

31. The method of claim 30, wherein the cytokine is GM-CSF.

32. The method of claim 30, wherein the cytokine is interleukin 2.

Serial No.: 08/955,373
Atty. Docket No.: 162/P58774US3

33. The method of claim 29, wherein the modified self-protein is a modified cytokine selected from the group consisting of modified TNF- α , modified TNF- β and modified γ -interferon.

34. The method of claim 33, wherein the modified cytokine is modified TNF- α .

35. The method of claim 33, wherein the modified cytokine is modified TNF- β .

E2 36. The method of claim 33, wherein the modified cytokine is modified γ -interferon.

37. The method of claim 29, wherein the modified self protein is modified IgE.

38. The method of claim 33, wherein the antibodies produced are effective in treating or ameliorating cachexia.

Serial No.: 08/955,373
Atty. Docket No.: 162/P58774US3

39. The method of claim 38, wherein antibodies produced are antibodies against modified TNF- α .

40. The method of claim 38, wherein antibodies produced are antibodies against modified γ -interferon.

41. The method of claim 37, wherein the antibodies produced are effective in treating or ameliorating allergy.

E2 42. The method of claim 33, wherein the antibodies produced are effective in treating or ameliorating chronic inflammatory disease.

43. The method of claim 34, wherein the antibodies produced are effective in treating or ameliorating diabetes mellitus.

44. The method of claim 26, wherein the modified self-protein is modified by substituting, by molecular and biological means, one or more peptide fragments of the self protein by a corresponding